NBE Therapeutics, a company developing next-generation antibody-drug conjugates (ADCs), recently announced the closing of a CHF 20 m Series B financing round and a collaboration with SOTIO a.s. for the discovery, non-clinical development and manufacturing of novel ADC products. As part of the deal, the PPF Group has committed to invest CHF 10 m in NBE. VISCHER has been advising the PPF Group in the financing transaction. The team was led by Matthias Staehelin (Corporate) with Dania Salvisberg-Schneider (Corporate) and Luzius Zumstein (Corporate).